Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin

moxifloxacin has been researched along with 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin in 2 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)		Trials
(3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)		Recent Studies (post-2010) (3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin)
3,1575521,690123911

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP1
Cierpicki, T; Franzblau, SG; Garcia, GA; Gill, SK; Kirchhoff, PD; Peng, KW; Showalter, HD; Turbiak, AJ; Wan, B; Xu, H; Zhang, N1

Other Studies

2 other study(ies) available for moxifloxacin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin

ArticleYear
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States

2007
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.
    Journal of medicinal chemistry, 2012, Apr-26, Volume: 55, Issue:8

    Topics: Animals; Antibiotics, Antitubercular; Benzoxazines; DNA-Directed RNA Polymerases; Drug Design; Drug Resistance, Bacterial; Mice; Mycobacterium tuberculosis; Rifampin; Rifamycins

2012